Physician profile
John E Marquez
NPI 1023153723
$10,545.13
in general payments reported to CMS, 2019-2025
36 companies · $2,572 in 2025
The $2,572 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $943 · 2022: $1,121 · 2023: $3,410 · 2024: $2,499 · 2025: $2,572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,911 · Consulting Fee: $1,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,910.89 |
| Consulting Fee | $1,570.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $4,204.10 | 2021-2025 | Biktarvy |
| Viiv Healthcare Company | $1,771.16 | 2022-2025 | Dovato, Apretude, Cabenuva |
| Abbvie INC. | $1,580.24 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $397.84 | 2023-2025 | Rexulti, Abilify Maintena |
| Astrazeneca Pharmaceuticals Lp | $354.92 | 2021-2025 | Breztri, Airsupra, Nexium |
| Lilly USA, LLC | $297.71 | 2021-2025 | Kisunla, Zepbound, Mounjaro |
| Pfizer INC. | $278.29 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $194.67 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $173.44 | 2023-2025 | Pifeltro, Delstrigo, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.75 | 2021-2024 | Xifaxan, Trulance |
| Vanda Pharmaceuticals INC. | $129.65 | 2021-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.07 | 2023-2025 | Caplyta |
| Exact Sciences Corporation | $102.08 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company Ltd. | $81.96 | 2022 | |
| Astellas Pharma US INC | $70.60 | 2021-2025 | Veozah |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $63.26 | 2023-2024 | Quviviq |
| Aimmune Therapeutics, INC. | $61.95 | 2025 | Zenpep |
| Genentech USA, INC. | $58.13 | 2021-2022 | |
| Lundbeck LLC | $52.64 | 2023-2024 | Rexulti |
| Novo Nordisk INC | $50.39 | 2022-2025 | |
| Exeltis, USA INC. | $33.26 | 2023 | Slynd |
| Nestle Healthcare Nutrition INC. | $31.37 | 2022 | |
| Boston Scientific Corporation | $25.07 | 2024 | |
| Axsome Therapeutics, INC. | $24.43 | 2025 | Symbravo |
| Alkermes, INC. | $24.38 | 2023 | Vivitrol |
| Allergan, INC. | $24.23 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.92 | 2022 | |
| Phadia US INC. | $23.58 | 2024 | Immunocap |
| Biohaven Pharmaceuticals, INC. | $22.80 | 2021 | |
| Esperion Therapeutics, INC. | $20.75 | 2021 | |
| Sumitomo Pharma America, INC. | $17.05 | 2024 | Gemtesa |
| Organon LLC | $16.16 | 2023 | Nexplanon |
| Currax Pharmaceuticals LLC | $15.45 | 2025 | Contrave |
| Philips North America LLC | $14.60 | 2024 | (Ck7) Extended Holter |
| Inspire Medical Systems, INC. | $14.35 | 2025 | Inspire |
| Ibsa Pharma INC. | $12.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Marquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.